Analyzing the Scope and Claims of United States Patent 5,212,200: A Comprehensive Guide
Introduction
United States Patent 5,212,200, titled "Compositions and Methods for Reducing Ocular Hypertension," is a significant patent in the field of ophthalmology. This patent, granted to various inventors and assignees over the years, outlines innovative compositions and methods for treating ocular hypertension and glaucoma. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background of the Patent
Patent Overview
The patent, issued on May 18, 1993, describes compositions and methods for reducing intraocular pressure (IOP) using prostaglandin analogs. This invention is crucial for managing conditions like glaucoma, which can lead to vision loss if not properly treated[4].
Inventors and Assignees
The patent lists several inventors and assignees who contributed to the development of these compositions and methods. Understanding the roles of these individuals and entities can provide insights into the collaborative efforts behind the patent.
Scope of the Patent
Technical Description
The patent details the use of specific prostaglandin analogs, such as those derived from prostaglandin F2α, to reduce IOP. The preferred prostaglandin concentration is an amount that substantially reduces the IOP of an eye. This technical description is critical for understanding the mechanism of action and the efficacy of the treatment[4].
Claims
The patent includes multiple claims that define the scope of the invention. These claims typically cover:
- Composition Claims: Specific formulations of prostaglandin analogs and their concentrations.
- Method Claims: Procedures for administering these compositions to reduce IOP.
- Use Claims: The therapeutic uses of these compositions, including the treatment of ocular hypertension and glaucoma.
Claim Analysis
To understand the patent's scope, it is essential to analyze each claim. For example:
- Claim 1 might describe a composition comprising a specific prostaglandin analog.
- Claim 2 could outline a method for administering this composition to a patient.
- Claim 3 might specify the use of this composition for reducing IOP.
Each claim must be carefully examined to determine the breadth and specificity of the patent's protection.
Patent Landscape
Related Patents
The patent landscape includes other patents related to ocular hypertension and glaucoma treatments. For instance, patents like US-20030220396-A1 also address methods for treating ocular hypertension, although they may use different approaches or compounds[2].
International Patent Filings
The invention described in US Patent 5,212,200 may have been filed in other countries as well. For example, a similar patent (CA 2280089) was granted in Canada, highlighting the global reach of this invention[4].
Global Dossier and IP5 Offices
Using tools like the Global Dossier, one can access the file histories of related applications from participating IP Offices, including the IP5 Offices (USPTO, EPO, JPO, KIPO, and CNIPA). This helps in understanding the global patent family and any office actions related to these patents[1].
Search and Analysis Tools
USPTO Resources
The USPTO provides several resources for searching and analyzing patents, including the Patent Public Search tool, which replaced legacy search tools like PubEast and PubWest. This tool offers enhanced access to prior art and is crucial for conducting thorough patent searches[1].
Patent Claims Research Dataset
The USPTO's Patent Claims Research Dataset can be used to analyze claims from U.S. patents, including those related to US Patent 5,212,200. This dataset provides detailed information on claims and their dependency relationships, which can help in understanding the patent's scope and claims[3].
International Patent Databases
European Patent Office (EPO)
Databases like esp@cenet from the EPO provide access to European patent collections and machine translations of European patents. This is useful for comparing and contrasting the claims and scope of US Patent 5,212,200 with its European counterparts[1].
Other International Databases
Similar databases from other international intellectual property offices, such as the Japan Patent Office (JPO) and the World Intellectual Property Organization (WIPO), offer additional resources for global patent searches and analyses[1].
Practical Applications and Impact
Clinical Use
The compositions and methods described in US Patent 5,212,200 have significant clinical applications. They provide effective treatments for reducing IOP, which is a critical aspect of managing glaucoma and preventing vision loss.
Economic Impact
The economic impact of this patent is substantial, given the prevalence of glaucoma and the need for effective treatments. The patent has likely influenced the development of various pharmaceutical products and treatment protocols.
Key Takeaways
- Patent Scope: The patent covers specific compositions and methods for reducing IOP using prostaglandin analogs.
- Claims Analysis: Each claim must be carefully analyzed to understand the breadth and specificity of the patent's protection.
- Patent Landscape: The patent is part of a broader landscape that includes related patents and international filings.
- Search and Analysis Tools: Utilizing tools like the USPTO's Patent Public Search and the Patent Claims Research Dataset is essential for thorough analysis.
- International Databases: Accessing international patent databases helps in understanding the global implications of the patent.
FAQs
What is the main invention described in US Patent 5,212,200?
The main invention is the use of specific prostaglandin analogs to reduce intraocular pressure (IOP) for treating ocular hypertension and glaucoma.
How can I search for related patents?
You can use the USPTO's Patent Public Search tool, Global Dossier, and international patent databases like esp@cenet from the EPO.
What are the key claims in US Patent 5,212,200?
The key claims include composition claims for prostaglandin analogs, method claims for administering these compositions, and use claims for treating ocular hypertension and glaucoma.
How does this patent impact clinical practice?
The patent has led to the development of effective treatments for reducing IOP, which is crucial for managing glaucoma and preventing vision loss.
Where can I find more detailed information on the patent's scope and claims?
You can use the USPTO's Patent Claims Research Dataset and consult the patent's full text available through the USPTO or other patent databases.
Sources
- USPTO: Search for patents - USPTO.
- Unified Patents Portal: US-20030220396-A1 - Unified Patents Portal.
- USPTO: Patent Claims Research Dataset - USPTO.
- Canadian Patents Database: Patent 2280089 Summary - Canadian Patents Database.
